Anti-snoring innovators secure 1.48m NIHR funding to tackle sleep apnoea at its source

"Zeus Sleep Ltd has been awarded £1.48 million in funding from the National Institute for Health and Care Research (NIHR) to lead one of the UK's largest multi-centre clinical trials into Obstructive Sleep Apnoea (OSA). The trial will be led by Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London, and will evaluate a next-generation, non-invasive medical device designed to address sleep apnoea by stimulating the airway at the source."

"OSA affects an estimated eight million people in the UK and more than one billion globally. The condition is characterised by repeated airway collapse during sleep, leading to fragmented rest, excessive daytime fatigue, increased cardiovascular risk and a higher likelihood of accidents. While Continuous Positive Airway Pressure (CPAP) therapy remains the NHS gold standard, more than half of patients abandon treatment within a year due to discomfort or inconvenience, often leaving lifestyle advice as the only alternative."

Zeus Sleep Ltd received £1.48 million from NIHR to lead a large UK multi-centre clinical trial assessing a next-generation, non-invasive device targeting OSA through airway stimulation. The trial is led by Guy's and St Thomas' NHS Foundation Trust with King's College London. Consumer research found 56% of adults report snoring negatively impacts life, with 36% forced to sleep separately and 11% fearing relationship deterioration. OSA affects about eight million people in the UK and over one billion globally, causing fragmented sleep, daytime fatigue, increased cardiovascular risk and higher accident likelihood. CPAP remains the NHS standard but has high abandonment rates; ZeusOSA is a home-wearable hypoglossal nerve stimulator planned for regulated medical launch in early 2026.

Read at Business Matters